DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)

Slides:

Advertisements

Similar presentations

Department of Neurology, Mayo Clinic Arizona

Advertisements

Agenda: - Update on master tracers’ segmentation check - Update validation vs pathology - PMT application submission of “Study on the validation of VSRAD”

©2011 MFMER | slide-1 Alzheimer Disease: Update Neill R. Graff-Radford, MBBCh, FRCP Professor of Neurology Mayo College of Medicine.

Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

Dementia with Lewy Bodies

Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.

Ethical issues in disclosing AD biomarker results Helen FK Chiu Professor of Psychiatry, The Chinese University of Hong Kong.

Pr Bruno Dubois Head of the Dementia Research Center (IMMA)

TEMPLATE DESIGN © All PET scans were processed to uniform resolution as implemented by ADNI (Joshi, 2009) to minimize.

Risk of Developing Alzheimer’s Disease in Persons with MCI

Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada.

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

AAN –Toronto, April 11, 2010 Development of a harmonized protocol for hippocampal tracing An EADC-ADNI joint effort INTRODUCTION.

The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.

Dr Hussein Farghaly PSMMC

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.

PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.

Alabama Brief Cognitive Screener (ABCs)

Clifford R Jack Jr MD Professor of Radiology

Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.

Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Alzheimer’s Disease: 진단과 치료

DECIDE EEG facilities FOR TRAINING AND DISSEMINATION of SCIENTIST profile: The basis of the EEG science for Alzheimer’s disease.

Advanced brain imaging and neurodegenerative disorders. Dott.ssa Ingrid Inches.

CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS

INFLUENCE OF FRACTIONAL ANISOTROPY THRESHOLD FOR TRACT BASED DIFFUSION TENSOR ANALYSIS OF UNCINATE FASCICLES IN ALZHEIMER DISEASE Toshiaki Taoka, Toshiaki.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.

WISCONSIN ALZHEIMER’S DISEASE RESEARCH CENTER

Update of China-ADNI Kuncheng Li, MD. PhD.

EUROPEAN ADNI/PharmaCOG

Investigating dementia

Volume 3, Issue 4, Pages (November 2017)

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Rosa Maria Moresco University of Milan Bicocca

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Volume 45, Pages 1-7 (September 2017)

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment Sanna-Kaisa Herukka,

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

PPMI in the Medical Literature

Early Dementia Distinguishing AD From MCI

TRENDS IN CNS DEVELOPMENT

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

Volume 10, Issue 3, Pages (January 2015)

Blood-Based Biomarkers in the QC Program?

Probing the Biology of Alzheimer's Disease in Mice

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Update of China-ADNI Kuncheng Li, MD. PhD.

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W

Ajdina Karic and Almira Bogdanic 13th November, 2018

A patient with early Alzheimer disease, 77 years of age, Mini-Mental State Examination score = 25. A patient with early Alzheimer disease, 77 years of.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Biomarker Modeling of Alzheimer’s Disease

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Progress Seminar 권순빈.

Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.

Figure 2 Global tau-PET distribution in familial prion disease mirrors the distribution seen in Alzheimer disease Global tau-PET distribution in familial.

Figure 2 Neuroimaging characteristics of TARDBP carriers

Figure 2 Aβ-PET scans obtained using different tracers

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)

2

3

4

5

AD Mild cognitive impairment (MCI) APPLICATION TO CLINICAL NEUROPHYSIOLOGY Which markers for early diagnosis, prognosis, and monitoring of Alzheimer disease? Normal elderly (Nold)

Structure: MR hippo volumetry Biochemistry: CSF tau/Abeta Function: FDG PET Amyloid deposits: PET Dubois, Feldman et al., Lancet Neurol 2007 Revised NIA-AA diagnostic criteria Biomarkers

Genetic risk of AD: ApoE4 9 Jack et al., 2010, Lancet Neurology

Staging AD with dynamic biomarkers: CSF, PET and MRI 10 Jack et al., 2010, Lancet Neurology

DEVELOP STANDARDIZED OPERATIONAL PROCEDURES FOR DIAGNOSTIC MARKERS ModalityCollectionMeasurement Hippocampal volume 3D T1 MR ADNI protocol Alzheimer’s Association / EADC-ADNI harmonized protocol (under development) Temporo-parietal hypometabolism FDG PET ADNI protocol Head-to-head comparison of scores (under development) CSF Ab42 and tau Lumbar puncture Alzheimer’s Association protocol (under development) Cortical amyloid deposition Amyloid PET None

Basic methodology: electrode montage and LORETA for source analysis of resting eyes-closed EEG electrode system Resting eyes closed (2 min), eyes open (2 min) LORETA LORETA solutions averaged with cortical lobes (frontal, central, parietal, temporal, occipital, limbic) Psychometric testing and neurological evaluation CHEAP, NON-INVASIVE, AND DIFFUSE CANDIDATE MARKERS FOR FIRST SCREENING: RESTING STATE EEG

Babiloni C, Binetti G, Cassetta E, Cerboneschi D, Dal Forno G, Del Percio C, Ferreri F, Ferri R, Lanuzza B, Miniussi C, Moretti DV, Nobili F, Pascual-Marqui RD, Rodriguez G, Romani GL, Salinari S, Tecchio F, Vitali P, Zanetti O, Zappasodi F, Rossini PM. Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study. Neuroimage. 2004; 22(1): Posterior sources of resting alpha rhythms were lower in power in mild AD than VaD subjects, despite similar degree of global cognition. Resting EEG data: 38 Nold 48 mild AD 20 VaD